RxDoctor Payments Data

Martin Handler, MD

Cardiovascular Disease · Roslyn, NYNPI 1326114315

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 111 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$674
  • Johnson & Johnson$345
  • Pfizer$304
  • E.r. Squibb & Sons, L.L.C.$272
  • AstraZeneca$165
  • Kowa Pharmaceuticals America, Inc.$80
  • plus $130 from 3 others

What the payments were for

  • Food & beverage$1,970100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,970 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,145,229
Medicare patients
671
Services billed
17,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$206,436
XareltoRivaroxaban50$67,988
EntrestoSacubitril/Valsartan14$26,632
Repatha SureclickEvolocumab23$13,012
Rosuvastatin Calcium253$4,968
Ezetimibe-SimvastatinEzetimibe/Simvastatin25$4,640
Prasugrel Hcl44$3,682
Atorvastatin Calcium281$3,300
Metoprolol Succinate152$2,881
Amlodipine Besylate333$2,735
Digoxin74$2,251
Ezetimibe69$1,892
Metoprolol Tartrate162$1,726
Enalapril Maleate42$1,590
Losartan Potassium107$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$304$206,436158 claims
Johnson & JohnsonXarelto$345$67,98850 claims
NovartisEntresto$674$26,63214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →